Although the developmental advantage might enhance the antitumor immunity in Cnr2-deficient mice, we found that shRNA knockdown of Cnr2 in wild-type OT-I T cells greatly enhanced their activities against tumor. The gene discussed is CNR2; the disease is neoplasm.